Comparing Four Cell-Penetrating Peptides for Delivering Cancer-Targeting Proteins Inside Breast Cancer Cells | Research

The takeaway

Of four endosomolytic peptides tested for intracellular protein delivery, only Aurein 1.2 and GALA enhanced cell entry while maintaining the ability to specifically target EGFR-positive breast cancer cells.

2 of 4 peptides maintained targeting
Only Aurein 1.2 and GALA preserved EGFR specificity while enhancing intracellular delivery — HA2 and L17E sacrificed targeting precision for cell entry

What the researchers found

All four endosomolytic peptides (Aurein 1.2, GALA, HA2, and L17E) enhanced endosomal disruption when fused to EGFR-targeted protein conjugates, increasing the half-life of internalized protein and reducing lysosomal degradation. However, only Aurein 1.2 and GALA maintained EGFR-targeting specificity, while HA2 and L17E compromised the ability to selectively target cancer cells. This demonstrates that the choice of endosomal escape peptide significantly affects both targeting capability and bioactivity of the delivery system.

Why it matters

Most protein-based drugs can only reach targets on the outside of cells because getting proteins inside cells intact is extremely difficult. This research advances the design of peptide-based delivery systems that could unlock intracellular protein therapies for cancers like EGFR-positive breast cancer, while showing that not all delivery peptides are interchangeable — some sacrifice targeting precision for entry efficiency.

How the study worked

Researchers created fusion protein conjugates by attaching four different endosomolytic peptides (Aurein 1.2, GALA, HA2, L17E) to EGFR-targeted proteins. They systematically compared the conjugates in breast cancer cells using the Gal8-YFP assay to measure endosomal escape, along with assays for lysosomal colocalization, protein half-life, EGFR specificity, and cytotoxicity. This was an in vitro (cell culture) study.

What this study cannot tell us

All experiments were performed in cell culture (in vitro), so results may not directly translate to living organisms where factors like immune response, blood clearance, and tissue penetration come into play. The study tested only four endosomolytic peptides, and performance may vary with different target receptors or cell types beyond EGFR-positive breast cancer cells.

How to read the evidence

This is an in vitro (cell culture) study using a systematic comparison design. While it provides well-controlled mechanistic data, the findings have not been validated in animal models or clinical settings, placing it at a preclinical evidence level.

When this study was published

Published in 2022, this study reflects current approaches in peptide-mediated drug delivery research and remains highly relevant to the active field of intracellular biologics.

The bigger picture

The vast majority of approved protein drugs — including antibodies — can only target molecules on the cell surface because delivering proteins inside cells intact remains an unsolved problem at scale. This research contributes to a growing field of peptide-based intracellular delivery that could eventually enable therapies targeting previously 'undruggable' proteins inside cancer cells. The finding that different escape peptides have very different effects on targeting specificity is a critical insight for the field.

Questions still open

Would Aurein 1.2 and GALA maintain their targeting specificity and endosomal escape performance in animal models of EGFR-positive breast cancer?
Can these endosomolytic peptides be adapted for delivering proteins to other intracellular targets beyond EGFR, such as mutant p53 or RAS?
What structural features of Aurein 1.2 and GALA allow them to preserve receptor specificity while HA2 and L17E do not?

Common questions

What are endosomolytic peptides and why do they matter for drug delivery?

When proteins enter cells, they get trapped in bubble-like compartments called endosomes, where they are usually destroyed. Endosomolytic peptides can disrupt these endosome membranes, releasing the therapeutic protein into the cell interior where it can reach its target. This is a critical step for making protein-based drugs that work inside cells rather than just on the surface.

Why can't all protein drugs work inside cells?

Proteins are large, charged molecules that cannot easily cross cell membranes. When they do get inside through receptor-mediated uptake, they typically end up trapped in endosomes and are degraded by lysosomes before reaching their target. This study addresses the 'endosomal escape' problem using specialized peptides that punch holes in the endosome membrane to free the therapeutic cargo.

Read the original research

Incorporation of Endosomolytic Peptides with Varying Disruption Mechanisms into EGFR-Targeted Protein Conjugates: The Effect on Intracellular Protein Delivery and EGFR Specificity in Breast Cancer Cells.

Molecular pharmaceutics, 19(2), 661-673

View on PubMed ↗Publisher’s paper ↗

Citation

Lieser, Rachel M; Li, Qirun; Chen, Wilfred; Sullivan, Millicent O. (2022). Incorporation of Endosomolytic Peptides with Varying Disruption Mechanisms into EGFR-Targeted Protein Conjugates: The Effect on Intracellular Protein Delivery and EGFR Specificity in Breast Cancer Cells.. Molecular pharmaceutics, 19(2), 661-673. https://doi.org/10.1021/acs.molpharmaceut.1c00788